{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:51:28Z","timestamp":1792245088679,"version":"4.4.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>68Ga-Pentixafor PET\/CT, a molecular imaging technique targeting the C-X-C chemokine receptor 4 (CXCR4), has emerged as a promising tool in the diagnosis and therapeutic evaluation of lung cancer. Lung cancer remains a leading cause of cancer-related mortality worldwide, and accurate imaging modalities are critical for early detection, staging, and treatment monitoring. Current imaging approaches face challenges in differentiating tumor subtypes and assessing tumor biology, which limits personalized treatment strategies. This review systematically summarizes the application of 68Ga-Pentixafor PET\/CT across various histological subtypes of lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and rare lung cancer variants. We emphasize the correlation between PET imaging findings and immunohistochemical CXCR4 expression, highlighting the diagnostic value and unique imaging characteristics of this modality. Additionally, the potential role of 68Ga-Pentixafor PET\/CT in guiding radioligand therapy is discussed, alongside its utility in tumor staging, therapeutic response assessment, and individualized treatment planning. By integrating recent clinical studies and systematic evaluations, this review aims to elucidate the advantages and limitations of 68Ga-Pentixafor PET\/CT, providing theoretical insights and practical guidance for advancing precision medicine in lung cancer management.<\/jats:p>","DOI":"10.3389\/or.2026.1797818","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:47:45Z","timestamp":1776836865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Progress in the application of 68Ga-Pentixafor PET\/CT in lung cancer: a review"],"prefix":"10.3389","volume":"20","author":[{"given":"Lisheng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Jiulongpo District People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Chongqing University of Posts and Telecommunications","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.semnuclmed.2025.02.005","article-title":"Evolving paradigms in lung cancer: latest trends in diagnosis, management, and radiopharmaceuticals","volume":"55","author":"Cangut","year":"2025","journal-title":"Semin Nucl Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.clon.2022.08.036","article-title":"Early diagnosis and lung cancer screening","volume":"34","author":"Balata","year":"2022","journal-title":"Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/MNM.0000000000002049","article-title":"Chemokine receptor-4-targeted imaging with [68Ga]Ga-Pentixafor PET: unveiling its diagnostic and prognostic potential across cancers: a systematic review","volume":"46","author":"Taghizadehasl","year":"2025","journal-title":"Nucl Med Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00259-022-06059-2","article-title":"[68Ga]Ga-Pentixafor PET\/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors\u2019 density by immunochemistry techniques","volume":"50","author":"Watts","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s12149-025-02093-w","article-title":"Evaluating the diagnostic utility of [68Ga]Ga-Pentixafor in solid tumors: a systematic review","volume":"39","author":"Ruzzeh","year":"2025","journal-title":"Ann Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41419-022-04514-4","article-title":"Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0241240","DOI":"10.1371\/journal.pone.0241240","article-title":"CXCR4 expression in lung carcinogenesis: evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients","volume":"16","author":"Fung","year":"2021","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/cancers15010171","article-title":"Phenotypic characterization of circulating tumor cells isolated from non-small and small cell lung cancer patients","volume":"15","author":"Roumeliotou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12885-022-09756-1","article-title":"The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis","volume":"22","author":"Qiu","year":"2022","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41419-021-03509-x","article-title":"Cancer-associated fibroblast-derived SDF-1 induces epithelial-mesenchymal transition of lung adenocarcinoma via CXCR4\/\u03b2-catenin\/PPAR\u03b4 signalling","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1080\/21655979.2022.2052652","article-title":"Mesenchymal stem cells inhibited the apoptosis of alveolar epithelial cells caused by ARDS through CXCL12\/CXCR4 axis","volume":"13","author":"He","year":"2022","journal-title":"Bioengineered"},{"key":"B12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.22038\/AOJNMB.2024.77059.1545","article-title":"On the optimization of the protocol for automated radiosyntheses of [68Ga]Ga-Pentixafor, [68Ga]Ga-FAPI-4 and [68Ga]Ga-DOTATATE in a modular-lab standard","volume":"12","author":"Menon","year":"2024","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/diagnostics14131375","article-title":"Chemokine Receptor-4 targeted PET\/CT imaging with 68Ga-Pentixafor in head and neck Cancer-A comparison with 18F-FDG and CXCR4 immunohistochemistry","volume":"14","author":"Hadebe","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2174\/1389557523666221216095821","article-title":"Nuclear medicine application of pentixafor\/pentixather targeting CXCR4 for imaging and therapy in related disease","volume":"23","author":"Chen","year":"2023","journal-title":"Mini Rev Med Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","article-title":"[68Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT","volume":"51","author":"Chen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/RLU.0000000000003750","article-title":"Burkitt lymphoma\/leukemia presented on 68Ga-Pentixafor and 18F-FDG PET\/CT","volume":"47","author":"Chen","year":"2022","journal-title":"Clin Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/RLU.0000000000003760","article-title":"Chemokine receptor 4-Targeted 68Ga-Pentixafor PET\/CT in response assessment of waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: Comparison to 18F-FDG PET\/CT","volume":"46","author":"Pan","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11307-024-01913-1","article-title":"Comparison of [18F]FDG and [68 Ga]pentixafor PET\/CT in Nasopharyngeal Carcinoma","volume":"26","author":"Liu","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9288","DOI":"10.18632\/oncotarget.7063","article-title":"[68Ga]PentixaforPET\/CT for imaging of chemokine receptor 4 expression in small cell lung cancer initial experience","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2967\/jnmt.122.264141","article-title":"68Ga-Pentixafor PET\/CT demonstrating in vivo CXCR4 receptor overexpression in rare lung malignancies: correlation with histologic and histochemical findings","volume":"50","author":"Watts","year":"2022","journal-title":"J Nucl Med Technol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MNM.0000000000001719","article-title":"Diagnostic value of [ 68 Ga]Ga-Pentixafor versus [ 18 F]FDG PET\/cTs in non-small cell lung cancer: a head-to-head comparative study","volume":"44","author":"Mirshahvalad","year":"2023","journal-title":"Nucl Med Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00259-023-06547-z","article-title":"CXCR4-directed PET\/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology","volume":"51","author":"Dreher","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2967\/jnumed.121.263693","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1007\/s00259-024-06704-y","article-title":"Targeting CXCR4\/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer","volume":"51","author":"Bao","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40644-021-00391-w","article-title":"Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach","volume":"21","author":"Linde","year":"2021","journal-title":"Cancer Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2967\/jnumed.121.262206","article-title":"68Ga-Pentixafor PET\/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms","volume":"63","author":"Kraus","year":"2022","journal-title":"J Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12020-024-04024-7","article-title":"Typing diagnostic value of 68Ga-pentixafor PET\/CT for patients with primary aldosteronism and unilateral nodules","volume":"87","author":"Zuo","year":"2025","journal-title":"Endocrine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/cancers17050763","article-title":"Comparing 68Ga-Pentixafor,18F-FDG PET\/CT and chemokine receptor 4 immunohistochemistry staining in breast cancer: a prospective cross sectional study","volume":"17","author":"Hadebe","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B29","first-page":"208","article-title":"Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET\/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [18F]FDG","volume":"13","author":"Zhi","year":"2023","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13550-021-00822-6","article-title":"Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients","volume":"11","author":"Lewis","year":"2021","journal-title":"EJNMMI Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/diagnostics12092135","article-title":"Current status of 68Ga-Pentixafor in solid tumours","volume":"12","author":"Hadebe","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1053\/j.semnuclmed.2025.02.006","article-title":"Impact of [18F]FDG PET\/CT radiomics and artificial intelligence in clinical decision making in lung cancer: its current role","volume":"55","author":"Safarian","year":"2025","journal-title":"Semin Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1133164","DOI":"10.3389\/fonc.2023.1133164","article-title":"The role of artificial intelligence based on PET\/CT radiomics in NSCLC: disease management, opportunities, and challenges","volume":"13","author":"Hu","year":"2023","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/cancers17193165","article-title":"Artificial intelligence-enhanced liquid biopsy and radiomics in early-stage lung cancer detection: a precision oncology paradigm","volume":"17","author":"Cherukuri","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jmrs.860","article-title":"A comprehensive review on the application of artificial intelligence for predicting postsurgical recurrence risk in early-stage non-small cell lung cancer using computed tomography, positron emission tomography, and clinical data","volume":"72","author":"Mehri-Kakavand","year":"2025","journal-title":"J Med Radiat Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3390\/cancers17152549","article-title":"Recent advances in PET and radioligand therapy for lung cancer: FDG and FAP","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/bioengineering10060690","article-title":"Automated classification of lung cancer subtypes using deep learning and CT-Scan based radiomic analysis","volume":"10","author":"Dunn","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"105050","DOI":"10.1016\/j.ejmp.2025.105050","article-title":"Imaging-aided diagnosis and treatment based on artificial intelligence for pulmonary nodules: a review","volume":"136","author":"Gao","year":"2025","journal-title":"Phys Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/life15030498","article-title":"New perspectives on lung cancer screening and artificial intelligence","volume":"15","author":"Duranti","year":"2025","journal-title":"Life (Basel)"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1797818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:47:47Z","timestamp":1776836867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1797818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":39,"alternative-id":["10.3389\/or.2026.1797818"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1797818","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1797818"}}